

# Noble Life Sciences Newsletter - January 2013



301-861-0009

800-602-9950

[www.noblelifesci.com](http://www.noblelifesci.com)

## **MORE THAN A CRO – YOUR PRECLINICAL DRUG DEVELOPMENT PARTNER**

**CELL & ANIMAL DISEASE MODELS \* PROTEIN PRODUCTION \* BIOMARKER DEVELOPMENT \* VIVARIUM SERVICES**

### ***Welcome to Noble Life Sciences News***

***Would you like to access a top-tier scientific team that can provide leadership and direction to optimize your research strategies... or simply execute your work plan with quality, speed and integrity? If so, contact Noble Life Sciences.***

***In this our first newsletter, we provide an overview of our capabilities, highlight one of our projects for an early stage pharmaceutical company, and introduce our CSO.***

***Click on the links in the newsletter for more information or contact us if you would like to discuss how we can help you accelerate your drug development program.***

***Alain Cappeluti  
President, Noble Life Sciences***

**Noble Life Sciences** Our continuum of preclinical research services includes a best-in-class vivarium, cell and animal disease models, preclinical protein and monoclonal antibody production, and a biomarker selection and validation process.

**Conserve cash** Plug into a highly effective, integrated set of scientific and management capabilities designed to advance your program to the next key milestones.

### **Oncology – a key core competency**

Let our experts advance your cancer drug development program. The Noble Life Sciences team has extensive experience in all facets of oncology drug development. With an intimate understanding of tumor pathways, drug targets, cell lines, xenograft models and biomarkers, we can work with you to determine the right experiments to advance your oncology program.

For more information visit [www.noblelifesci.com](http://www.noblelifesci.com) or e-mail our Director of Sales, Katie Butler, at [kbutler@noblelifesci.com](mailto:kbutler@noblelifesci.com).

Noble delivers nine monoclonal antibodies and a complex fusion protein in 10 weeks for NexImmune's cancer vaccine program.

For more information, [click here](#)

**Meet Noble's CSO  
Dr. Steve Horrigan, Chief Scientific Officer**

*"Working with Steve has been a true scientific collaborative experience. Steve and his team have exceeded our expectations in our recent xenograft study." Dr. Mariusz W. Szkudlinski, VP & CSO, Trophogen Inc.*

Prior to joining Noble, Steve was the VP of Research at Avalon Pharmaceuticals where he directed internal drug discovery and collaborative development programs with large pharmaceutical companies. He also played a key leadership role in the development of the company's unique genomic biomarker-driven R&D platform. Prior to joining Avalon, Steve was Associate Professor in the Department of Pediatrics and Lombardi Cancer Center at Georgetown University Medical Center where he led a research group focused on cancer genomics and the application of biomarkers in cancer diagnostics.